Sanofi (NASDAQ:SNY) Hits New 12-Month Low – Here’s Why

Sanofi (NASDAQ:SNY) shares reached a new 52-week low during trading on Friday. The company traded as low as $39.52 and last traded at $39.6180, with a volume of 630110 shares changing hands. The stock had previously closed at $40.67.

Key Stories Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi and Regeneron added four next-generation, long-acting antibodies to their global alliance, including clinical-stage IL-13 antibody REGN20423, a long-acting IL-4/IL-13 bispecific, and two preclinical candidates. The products could extend the companies’ leadership in type 2 inflammation and build on the success of Dupixent. Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
• Positive Sentiment: Regeneron will receive a $1 billion upfront payment, while Sanofi gains access to additional long-acting medicines that may offer more convenient dosing and improved commercial positioning. The companies will share development and commercialization costs and future profits equally. Sanofi, Regeneron Expand Immunology Partnership in $1 Billion Deal
• Neutral Sentiment: The agreement could be worth up to $8 billion, including as much as $7 billion in milestone payments. However, those payments depend on clinical, regulatory, and commercial success, so the pipeline’s eventual financial contribution remains uncertain. Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Billion
• Negative Sentiment: The immediate $1 billion cash outlay and Sanofi’s commitment to fund half of development costs increase near-term spending before the new antibodies generate revenue. The assets are also at different development stages, leaving meaningful execution and regulatory risk. Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SNY. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 29th. Royal Bank Of Canada assumed coverage on shares of Sanofi in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Morgan Stanley set a $49.00 price objective on shares of Sanofi in a report on Wednesday, July 8th. Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Down 2.0%

The stock’s 50 day simple moving average is $43.47 and its two-hundred day simple moving average is $44.18. The firm has a market cap of $96.60 billion, a P/E ratio of 20.86, a P/E/G ratio of 1.24 and a beta of 0.33. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period last year, the firm posted $3.24 earnings per share. As a group, research analysts forecast that Sanofi will post 5.07 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently made changes to their positions in the business. Physician Wealth Advisors Inc. grew its position in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares during the period. Western Wealth Management LLC bought a new position in Sanofi in the first quarter worth approximately $29,000. Leonteq Securities AG raised its position in Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after acquiring an additional 297 shares during the period. Fairway Wealth LLC purchased a new position in shares of Sanofi during the 1st quarter worth $32,000. Finally, Purpose Unlimited Inc. purchased a new position in shares of Sanofi during the 4th quarter worth $36,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.